Suhail Ayesh

Corporate Officer/Principal at The Hebrew University of Jerusalem

Health Technology

Consumer Services

Profile

Suhail Ayesh is Senior Researcher of BioCancell Therapeutics, Inc. He is Professor of Molecular Biochemistry and Gene Therapy at the Hebrew University of Jerusalem.
Mr. Ayesh is a Director of the Molecular Genetics Laboratory for Makassed Hospital.

Suhail Ayesh active positions

Companies	Position	Start
The Hebrew University of Jerusalem	Corporate Officer/Principal	-
Al-Makassed Hospital	Corporate Officer/Principal	-

All active positions of Suhail Ayesh

Former positions of Suhail Ayesh

Companies	Position	End
BioCancell Therapeutics, Inc. BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.	Chief Tech/Sci/R&D Officer	-

See the detail of Suhail Ayesh's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Suhail Ayesh's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
BioCancell Therapeutics, Inc. BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.	Health Technology
Al-Makassed Hospital